Drug Companies Back Again to Protect Patents for Biologics and Insulin
Like a clump of Scotch broom sprouting each year on Oregon hillsides no matter how many times it gets pulled, the pharmaceutical companies are repeating their efforts from past sessions to restrict the ability of pharmacists to dispense generic or “biosimilar” alternatives to so-called biological